EAM Investors LLC acquired a new stake in Verastem, Inc. (NASDAQ:VSTM) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 445,017 shares of the biopharmaceutical company’s stock, valued at approximately $2,092,000. EAM Investors LLC owned about 1.20% of Verastem at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Alpine Woods Capital Investors LLC bought a new stake in shares of Verastem in the 2nd quarter valued at approximately $109,000. Northern Trust Corp raised its holdings in shares of Verastem by 40.3% in the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 21,178 shares during the period. OxFORD Asset Management LLP purchased a new stake in shares of Verastem in the second quarter worth approximately $234,000. ClariVest Asset Management LLC purchased a new stake in shares of Verastem in the third quarter worth approximately $421,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Verastem by 697.6% in the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 253,492 shares during the period. 26.04% of the stock is owned by institutional investors and hedge funds.

Shares of Verastem, Inc. (NASDAQ VSTM) opened at $3.68 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12. Verastem, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $5.71.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.29). research analysts anticipate that Verastem, Inc. will post -1.76 EPS for the current year.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/24/eam-investors-llc-invests-2-09-million-in-verastem-inc-vstm.html.

Several equities research analysts have recently weighed in on VSTM shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $6.00 price target on shares of Verastem in a report on Thursday, October 12th. Zacks Investment Research downgraded Verastem from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Cantor Fitzgerald set a $17.00 price target on Verastem and gave the stock a “buy” rating in a report on Tuesday, October 31st. ValuEngine downgraded Verastem from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Cann reiterated a “buy” rating on shares of Verastem in a report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $7.18.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.